{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:27:22Z","timestamp":1788582442132,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jad.2024.10.112","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:27:30Z","timestamp":1730107650000},"page":"134-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effect of CYP3A5*3 genotype on exposure and efficacy of quetiapine: A retrospective, cohort study"],"prefix":"10.1016","volume":"370","author":[{"given":"Yan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizhao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jad.2024.10.112_bb0005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/FTD.0000000000000135","article-title":"Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients","volume":"37","author":"Bakken","year":"2015","journal-title":"Ther. Drug Monit."},{"issue":"9","key":"10.1016\/j.jad.2024.10.112_bb0010","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1124\/dmd.112.045237","article-title":"Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro","volume":"40","author":"Bakken","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.jad.2024.10.112_bb0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41431-023-01347-3","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics","volume":"32","author":"Beunk","year":"2024","journal-title":"European journal of human genetics\u202f: EJHG"},{"issue":"3","key":"10.1016\/j.jad.2024.10.112_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.18773\/austprescr.2015.032","volume":"38","author":"Brett","year":"2015","journal-title":"Concerns about quetiapine Australian prescriber"},{"issue":"7","key":"10.1016\/j.jad.2024.10.112_bb0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: an atypical antipsychotic","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jad.2024.10.112_bb0030","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3109\/15563650.2011.624100","article-title":"Clinical and analytical features of severe suicidal quetiapine overdoses--a retrospective cohort study","volume":"Pa.), 49(9)","author":"Eyer","year":"2011","journal-title":"Clinical toxicology Philadelphia"},{"issue":"4","key":"10.1016\/j.jad.2024.10.112_bb0035","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bcpt.12093","article-title":"Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?","volume":"113","author":"Herbild","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"1\u221202","key":"10.1016\/j.jad.2024.10.112_bb0040","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"9","key":"10.1016\/j.jad.2024.10.112_bb0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"1","key":"10.1016\/j.jad.2024.10.112_bb0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FPC.0000000000000020","article-title":"Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers","volume":"24","author":"Kim","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"issue":"4","key":"10.1016\/j.jad.2024.10.112_bb0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.jad.2024.10.112_bb0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.clpt.6100090","article-title":"Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil","volume":"81","author":"Langaee","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.jad.2024.10.112_bb0065","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1060028019829494","article-title":"Impact of quetiapine therapy on QTc prolongation in critically ill patients","volume":"53","author":"Lee","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jad.2024.10.112_bb0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.11.008","article-title":"Effects of quetiapine on sleep: a systematic review and meta-analysis of clinical trials","volume":"67","author":"Lin","year":"2023","journal-title":"European neuropsychopharmacology\u202f: the journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2024.10.112_bb0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jad.2024.01.170","article-title":"The impact of CYP3A5*3 on oral quetiapine: a population pharmacokinetic model in Chinese bipolar disorder patients","volume":"351","author":"Lin","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.jad.2024.10.112_bb0080","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jat\/28.6.443","article-title":"A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism","volume":"28","author":"Lin","year":"2004","journal-title":"J. Anal. Toxicol."},{"issue":"38","key":"10.1016\/j.jad.2024.10.112_bb0085","first-page":"2675","article-title":"Polymorphisms of drug-metabolizing enzymes genes in a Han Chinese population","volume":"89","author":"Liu","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.jad.2024.10.112_bb0090","first-page":"102","article-title":"Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders","volume":"4","author":"L\u00f3pez-Mu\u00f1oz","year":"2013","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2024.10.112_bb0095","first-page":"11","article-title":"The factors affecting the serum concentrations of quetiapine fumarate and their relationship with side effect in patients with schizophrenia [J]","volume":"05","author":"MA","year":"2018","journal-title":"Chin J Clin Ration Drug Use"},{"issue":"12","key":"10.1016\/j.jad.2024.10.112_bb0100","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical pharmacokinetics of atypical antipsychotics: an update","volume":"57","author":"Mauri","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.jad.2024.10.112_bb0105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2024.10.112_bb0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/cpdd.172","article-title":"Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment","volume":"4","author":"Shilbayeh","year":"2015","journal-title":"Clinical pharmacology in drug development"},{"issue":"12","key":"10.1016\/j.jad.2024.10.112_bb0115","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/bcp.15849","article-title":"Impact of age, sex and cytochrome P450 genotype on quetiapine and N-desalkylquetiapine serum concentrations: a study based on real-world data from 8118 patients","volume":"89","author":"Solhaug","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jad.2024.10.112_bb0120","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.09r05739yel","article-title":"Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review","volume":"72","author":"Sparshatt","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.10.112_bb0125","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/JCP.0000000000000070","article-title":"The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients","volume":"34","author":"van der Weide","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.jad.2024.10.112_bb0130","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/pharmaceutics13101573","article-title":"Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter quetiapine pharmacokinetics","volume":"13","author":"Zubiaur","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724018068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724018068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T22:18:07Z","timestamp":1736806687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724018068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"alternative-id":["S0165032724018068"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.10.112","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of CYP3A5*3 genotype on exposure and efficacy of quetiapine: A retrospective, cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.10.112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}